Exchange Traded Concepts LLC Buys New Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Exchange Traded Concepts LLC purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 26,224 shares of the company’s stock, valued at approximately $818,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SeaCrest Wealth Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 16.6% during the fourth quarter. SeaCrest Wealth Management LLC now owns 53,865 shares of the company’s stock worth $1,745,000 after purchasing an additional 7,680 shares during the last quarter. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 4.4% in the 4th quarter. Silverberg Bernstein Capital Management LLC now owns 95,317 shares of the company’s stock valued at $2,975,000 after purchasing an additional 4,000 shares during the last quarter. E. Ohman J or Asset Management AB acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $614,000. 180 Wealth Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at about $260,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Teva Pharmaceutical Industries by 3.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock worth $382,000 after buying an additional 379 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, Scotiabank upped their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $30.11 on Friday. The stock’s 50-day moving average price is $32.15 and its 200 day moving average price is $27.78. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $34.63 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 10.13 and a beta of 0.76. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same period last year, the firm earned $0.71 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the transaction, the insider directly owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. The trade was a 9.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric A. Hughes sold 9,533 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the transaction, the insider owned 107,711 shares of the company’s stock, valued at approximately $3,411,207.37. The trade was a 8.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 920,901 shares of company stock valued at $30,056,789. 0.49% of the stock is currently owned by company insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.